| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 387.65 | 2.9% | 181.5% |
| Total Income | 391.41 | 1.2% | 169.2% |
| Expenditure | 334.39 | 3.9% | 203.9% |
| PBT | 57.02 | 11.9% | 61.1% |
| Net Profit | 44.55 | 7.6% | 70.8% |
| OPM | 15.37% | 0.33pp | 7.16pp |
| NPM | 11.38% | 1.09pp | 6.55pp |
| EPS | 0.38 | 7.3% | 83.3% |
Detailed report is being prepared.
CrudeChem Momentum on Test; Margin Transition Pivotal
Fineotex Chemical pivots to a 65% oil-and-gas revenue mix post-CrudeChem integration. Q2 will reveal whether the 164% Q1 surge repeats and how margins reset as specialty chemicals cede ground to lower-margin oilfield services.
The Setup: Post-CrudeChem Fineotex
Fineotex Chemical's Q1 FY27 result (announced July 23, 2026) marked an inflection: consolidated total income surged 164% year-on-year to ₹386.72 Cr, with EBITDA climbing 134.69% to ₹59.14 Cr. The driver was the integration of CrudeChem Technologies Group, the oil-and-gas specialty-chemicals platform acquired in FY26, which now supplies nearly two-thirds of consolidated revenue. For Q2, the Street is watching two things: (1) whether momentum holds as the oil-and-gas services cycle tightens or loosens; and (2) how EBITDA margins reset as oilfield chemicals (lower-margin, higher-volume) displace specialty chemicals in the mix.
~₹380–420 Cr
USD 100M FY27 guidance = ~₹830 Cr annualized from oil & gas; specialty chemicals steady
15–16% est.
below Q1 EBITDA % as oil & gas displaces higher-margin specialty biz
YoY strong
but dependent on margin stabilization and tax rate
What a Strong vs. Weak Print Looks Like
Strong: Revenue tracks USD 100M FY27 run rate (~₹100–110 Cr/month from oil & gas), EBITDA margin holds 15%+ (signals CrudeChem margins better than feared), and management reiterates FY28 USD 200M oil & gas guidance. Weak: Revenue dips vs. Q1 (signals cycle softness in oilfield demand), EBITDA margin compresses below 14% (margin transition is sharper than expected), and management guides cautiously on FY28 or flags execution risk in the US subsidiary ramp-up announced in September.
On-Track Trajectory: FY27 Guidance vs. Reality
The company has reiterated USD 100M revenue from oil & gas in FY27, driven by customer demand and business visibility rather than crude-price assumptions. Q1 FY27 delivered consolidated revenue of ₹386.72 Cr, implying that CrudeChem + specialty chemicals is materially ahead of pre-acquisition run rates. For Q2 to be on-plan, revenue should hold in the ₹380–420 Cr band. A collapse below ₹350 Cr would signal either oil-cycle weakness or integration underperformance; a print above ₹420 Cr would suggest the USD 100M guidance is conservative. Management previously avoided fixed margin guidance, citing margin evolution; watch for any commentary on FY27–FY28 EBITDA % expectations.
What the Street Says
Since Last Quarter: Recent Filings & Corp Actions
1 · US Subsidiary Ramp-Up (Sep 2026)
Fineotex incorporated two US subsidiaries: Fineotex Holdings Inc. (Delaware) for specialty chemicals, and Fineotex America Inc. for advanced water-treatment chemicals. Both are wholly-owned step-down entities. No revenue guidance yet; watch for deployment capex and first-quarter revenue in Q3/Q4 FY27.
2 · Fundraising & Dividend (Aug 2026)
Board approved a fundraising proposal on Aug 17, 2026, to support expansion (likely US capex). Record date for final FY26 dividend: Sep 4, 2026. The fundraise underscores confidence in growth but also signals near-term capex demand; watch for dilution impact and use-of-proceeds disclosure.
3 · Ownership Drift (Latest Filings)
Promoter holding steady ~62.3% (Q1 FY27); FII ticked up 0.24pp to 3.16%, DII +0.09pp to 1.36%. No pledging flagged. Insider Irfan Shaikh's Oct 14 bulk buy (63L shares @ ₹60.04) is a positive signal; no other insider selling noted.
4 · AGM & FY26 Reports (Aug–Sep 2026)
23rd AGM held Sep 11, 2026. Revised FY26 annual report issued (typographical error corrected, Aug 18). BRSR (ESG report) filed. No major surprises; routine governance.
Three to Watch on Result Day (Nov 13)
1 · Revenue Momentum & Oilfield Cycle
Does Q2 revenue hold the ₹380–420 Cr run rate, or does it dip on softer oilfield demand (oil-services cycles can reverse rapidly)? Watch management commentary on customer order book and any Q3/Q4 booking visibility.
2 · EBITDA Margin Reset
EBITDA % on a consolidated basis is the key. Oil & gas is now 65% of revenue; if margins compress below 14%, the integration thesis weakens. Expect management to frame this as 'temporary mix effect' or 'scaling benefit coming'; measure their credibility against guidance.
3 · FY28 Guidance & US Capex
Any update on the USD 200M FY28 oil & gas guidance? Will management quantify US subsidiary capex and expected contribution? Capex intensity and cash-generation outlook will matter for the fundraise valuation.
Fineotex Chemical is at an inflection: a specialty-chemical business has become an oil-and-gas-driven scaled platform overnight via CrudeChem. Q2 earnings will show whether that transformation sticks. The Street is constructive (Buy consensus) and insider buying (Shaikh's Oct bulk buy) is a positive signal. However, coverage is thin, target prices cluster in a ₹47–₹57 range with the stock at ₹52.79, and analysts have flagged execution risk. The Q2 print—specifically revenue pace and EBITDA margin—will either validate the FY27–FY28 USD 100M–USD 200M oil & gas guidance or prompt a recalibration. Watch the margin bridge closely; the shift from 20%+ specialty-chemical EBITDA to 12–15% oilfield chemicals is real.